Drug chains, ASHP Support Anti-Price Gouging Campaign
Drug chains, ASHP Support Anti-Price Gouging CampaignA new campaign takes aim at drug prices, but is it the right approach?
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
How Vermont aims to cut drug spendingIf a proposed Vermont bill is successful, drug companies would have to explain why they hiked prices on certain drugs.
Pharma responds to critics with new drug adsPhRMA ad campaign features new patient and researcher stories.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
Oncology drugs in the pipelineSeveral new drugs hold promise, but cost is a top concern.
Be vigilant of counterfeit version of Botox found in United StatesA counterfeit version of onabotulinumtoxinA (Botox) was found in the United States and may have been sold to doctors’ offices and medical clinics nationwide. The version is considered unsafe and should not be used.
340B drug program causing controversyControversy surrounds the 340B Drug Discount Program, and many industry leaders agree that the healthcare law plays a large part.
HRSA withdraws proposed 340B ruleAgency will use guidance in 2015 to address “key policy issues.”
A prescription for specialty pharmaceuticals: Transparency and collaboration for improving drug and diagnosis coding on medical claimsSince the completion of the Human Genome Project, the explosive growth in molecular diagnostics and specialty pharmaceuticals is outpacing the growth seen in any prior era, raising serious concerns about clinical quality and cost. According to an industry survey conducted earlier this year by the Pharmaceutical Research and Manufacturers of America (PhRMA), more than 900 medicines and vaccines have been identified in various stages of development. To keep pace, the strategies that were adequate for the “empty pipeline” scenarios of a few years ago—to code each agent, communicate clinical evidence and clinical guideline developments, and update reimbursement methodologies—must now be enhanced.